Spotlight On... Kannalife considers an IPO; Biotech stalwart Mann dies at 90; and more...

New York biotech Kannalife Sciences is weighing an IPO in hopes of bankrolling its work on a cannabis-based treatment for a rare brain disorder. As Reuters reports, the company has a preclinical therapy for hepatic encephalopathy, a disease caused by blood toxins reaching the brain and affecting cognitive function. The plan, Kannalife said, is to raise between $5 million and $10 million in a mezzanine round before starting down the road to an IPO, according to Reuters. News

@FierceBiotech: Charities and pharma decry 'disgraceful' changes to England's Cancer Drugs Fund. Story | Follow @FierceBiotech

@JohnCFierce: Glad to see the top trending story yesterday was the Exicure profile. Doesn't always happen with little biotechs. Story | Follow @JohnCFierce

@DamianFierce: Wired is getting into dystopian fiction. Wired story | Follow @DamianFierce

> Longtime biotech entrepreneur Al Mann, founder of MannKind ($MNKD), has died at the age of 90. Story

> Peregrine Pharmaceuticals' ($PPHM) shares fell more than 60% after the company's lung cancer therapy bavituximab failed in Phase III. Item

Medical Device News

@FierceMedDev: ICYMI: Boston Scientific's Brazilian operations under investigation, as co-founder to depart. Story | Follow @FierceMedDev

@EmilyWFierce: Intel hops on the precision medicine bandwagon with new projects for 2016. News | Follow @EmilyWFierce

> FDA warns of unintentional head movement during surgery despite use of skull clamp. Story

> Boston upstart raises $46M, makes acquisition for translational imaging in biopharma R&D. More

Pharma News

@FiercePharma: Look out, drugmakers: NICE is taking the reins of England's Cancer Drugs Fund. Story | Follow @FiercePharma

@CarlyHFierce: ICYMI: Short on label expansions, Pfizer nabs FDA OK for new, once-daily Xeljanz. Story | Follow @CarlyHFierce

> Opdivo wins thumbs up from CHMP for two indications, in lung and kidney cancers. News

> Analyst: Valeant better bring back Pearson if it wants to stay in the game. More

Suggested Articles

Bayer's finerenone beat placebo at slowing kidney disease and cut the risk of heart attacks and strokes in diabetic kidney disease patients.

The National Institute of Allergy and Infectious Diseases is launching a new clinical trials network for COVID-19.

While Sanofi is looking to move more of its R&D in-house, there is still room for deals, and today it’s penned a big one with Fierce 15 winner Kymera